To gain a better understanding of the company, its product portfolio and its management team, BioAlliance Pharma organizes a symposium “Oncology: key issues for the future”

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced a half-day symposium:
“Oncology: key issues for the future”
On March 20, 2012 (from 9 am to 12 midday)
During the morning symposium, fund managers, analysts and media representatives will be invited to listen to and discuss with international leading specialists:
• Bertrand Vergely, Philosopher
• Pr. David Khayat, Professor in Oncology, La Pitié-Salpêtrière Hospital (Paris, France)
• Pr. Philippe Merle, Professor in Hepatology, La Croix Rousse Hospital (Lyon, France)
• Pr. Michael Henke, Professor in Radiotherapy, Universitätsklinikum Freiburg (Freiburg, Germany)
BioAlliance Pharma will be represented by:
• Judith Greciet, Chief Executive Officer
• Pierre Attali, Chief Operating Officer, Strategy and Medical Affairs
The event will take place at BioAlliance Pharma’s head office (in Paris) on Tuesday, March 20, 2012, from 9am onwards (by invitation only). The final morning’s program will be soon announced.

120201EN_SaveTheDate_Journee RD